Page 161 - 2021_07-Haematologica-web

Meta-analysis of radiotherapy for DLBCL
of radiotherapy to bulky disease in elderly patients with aggressive B-cell lymphoma. J Clin Oncol. 2014;32(11):1112-1118.
26. Casasnovas RO, Ysebaert L, Thieblemont C, et al. FDG-PET-driven consolidation strategy in diffuse large B-cell lymphoma: final results of a randomized phase 2 study. Blood. 2017;130(11):1315-1326.
27. dos Santos LV, Lima JP, Lima CS, Sasse EC, Sasse AD. Is there a role for consolidative radiotherapy in the treatment of aggressive and localized non-Hodgkin lymphoma? A systematic review with meta-analysis. BMC Cancer. 2012;12:288.
28.Held G, Zeynalova S, Murawski N, et al. Impact of rituximab and radiotherapy on outcome of patients with aggressive B-cell lymphoma and skeletal involvement. J Clin Oncol. 2013;31(32):4115-4122.
29. Recher C, Coiffier B, Haioun C, et al. Intensified chemotherapy with ACVBP plus rituximab versus standard CHOP plus ritux- imab for the treatment of diffuse large B-cell lymphoma (LNH03-2B): an open-label ran- domised phase 3 trial. Lancet. 2011;378 (9806):1858-1867.
30. Persky DO, Li H, Stephens DM, et al. PET- directed therapy for patients with limited- stage diffuse large B-cell lymphoma - results of Intergroup NCTN Study S1001. Blood. 2019;134(Suppl 1):S349.
31. Campbell BA, Connors JM, Gascoyne RD, Morris WJ, Pickles T, Sehn LH. Limited- stage diffuse large B-cell lymphoma treated with abbreviated systemic therapy and con- solidation radiotherapy: involved-field ver- sus involved-node radiotherapy. Cancer. 2012;118(17):4156-4165.
32. Sehn LH, Scott DW, Villa D, et al. Long-term follow-up of a PET-guided approach to treat- ment of limited-stage diffuse large B-cell lymphoma (DLBCL) in British Columbia (BC). Blood. 2019;134(Suppl 1):S401.
33. Sehn LH. Chemotherapy alone for localized diffuse large B-cell lymphoma. Cancer J. 2012;18(5):421-426.
34. Persky DO. Limited-stage DLBCL: it's patient selection. Blood. 2018;131(2):155-156.
35. A predictive model for aggressive non- Hodgkin's lymphoma. The International Non-Hodgkin's Lymphoma Prognostic Factors Project. N Engl J Med. 1993;329
(14):987-994.
36. Miller TP. The limits of limited stage lym-
phoma. J Clin Oncol. 2004;22(15):2982-
2984.
37. Poeschel V, Held G, Ziepert M, et al. Four
versus six cycles of CHOP chemotherapy in combination with six applications of ritux- imab in patients with aggressive B-cell lym- phoma with favourable prognosis (FLYER): a randomised, phase 3, non-inferiority trial. Lancet. 2020;394(10216):2271-2281.
38. Pfreundschuh M, Christofyllakis K, Altmann B, et al. Radiotherapy to bulky disease PET- negative after immunochemotherapy can be spared in elderly DLBCL patients: results of a planned interim analysis of the first 187 patients with bulky disease treated in the OPTIMAL > 60 study of the DSHNHL. J Clin Oncol. 2017;35(Suppl 15):S7506.
39. Ng AK, Yahalom J, Goda JS, et al. Role of radiation therapy in patients with relapsed/refractory diffuse large B-cell lym- phoma: guidelines from the International Lymphoma Radiation Oncology Group. Int J Radiat Oncol Biol Phys. 2018;100(3):652- 669.
40. Vitolo U, Seymour JF, Martelli M, et al. Extranodal diffuse large B-cell lymphoma (DLBCL) and primary mediastinal B-cell lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and fol- low-up. Ann Oncol. 2016;27(Suppl 5):v91- v102.
41. Yahalom J, Illidge T, Specht L, et al. Modern radiation therapy for extranodal lym- phomas: field and dose guidelines from the International Lymphoma Radiation Oncology Group. Int J Radiat Oncol Biol Phys. 2015;92(1):11-31.
42. Thiel E, Korfel A, Martus P, et al. High-dose methotrexate with or without whole brain radiotherapy for primary CNS lymphoma (G-PCNSL-SG-1): a phase 3, randomised, non-inferiority trial. Lancet Oncol. 2010;11(11):1036-1047.
43. Ferreri AJM, Cwynarski K, Pulczynski E, et al. Whole-brain radiotherapy or autologous stem-cell transplantation as consolidation strategies after high-dose methotrexate- based chemoimmunotherapy in patients with primary CNS lymphoma: results of the second randomisation of the International
Extranodal Lymphoma Study Group-32 phase 2 trial. Lancet Haematol. 2017;4(11): e510-e523.
44.Dunleavy K, Pittaluga S, Maeda LS, et al. Dose-adjusted EPOCH-rituximab therapy in primary mediastinal B-cell lymphoma. N Engl J Med. 2013;368(15):1408-1416.
45. Mamot C, Klingbiel D, Hitz F, et al. Final results of a prospective evaluation of the predictive value of interim positron emis- sion tomography in patients with diffuse large B-cell lymphoma treated with R- CHOP-14 (SAKK 38/07). J Clin Oncol. 2015;33(23):2523-2529.
46.Kurtz DM, Scherer F, Jin MC, et al. Circulating tumor DNA measurements as early outcome predictors in diffuse large B- cell lymphoma. J Clin Oncol. 2018;36(28): 2845-2853.
47. Duhrsen U, Müller S, Hertenstein B, et al. Positron emission tomography-guided ther- apy of aggressive non-Hodgkin lymphomas (PETAL): a multicenter, randomized phase III trial. J Clin Oncol. 2018;36(20):2024-2034.
48. Freeman CF, Savage KJ, Villa D, et al. Long- term results of PET-guided radiation therapy in patients with advanced-stage diffuse large B-cell lymphoma treated with R-CHOP in British Columbia. Blood. 2017;130(Suppl 1):S823.
49. Maurer MJ, Habermann TM, Shi Q, et al. Progression-free survival at 24 months (PFS24) and subsequent outcome for patients with diffuse large B-cell lymphoma (DLBCL) enrolled on randomized clinical tri- als. Ann Oncol. 2018;29(8):1822-1827.
50. Shi Q, Schmitz N, Ou FS, et al. Progression- free Survival as a surrogate end point for overall curvival in first-line diffuse large B- cell lymphoma: an individual patient-level analysis of multiple randomized trials (SEAL). J Clin Oncol. 2018;36(25):2593- 2602.
51. Specht L, Yahalom J. The concept and evolu- tion of involved site radiation therapy for lymphoma. Int J Clin Oncol. 2015;20(5):849- 854.
52.Torka P, Kothari SK, Sundaram S, et al. Outcomes of patients with limited-stage aggressive large B-cell lymphoma with high- risk cytogenetics. Blood Adv. 2020;4(2):253- 262.
haematologica | 2021; 106(7)
1931